{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T13:42:14Z","timestamp":1762090934709,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.humpath.2023.08.004","type":"journal-article","created":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T02:07:01Z","timestamp":1692842821000},"page":"130-138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["The clinical significance of increased large cells in marginal zone lymphoma"],"prefix":"10.1016","volume":"141","author":[{"given":"Travis","family":"Stueber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanya","family":"Jaitly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5387-2409","authenticated-orcid":false,"given":"Erika M.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2023.08.004_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21037\/aol-20-28","article-title":"Epidemiology of marginal zone lymphoma","volume":"5","author":"Cerhan","year":"2021","journal-title":"Annals of Lymphoma"},{"year":"2017","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow","key":"10.1016\/j.humpath.2023.08.004_bib2"},{"key":"10.1016\/j.humpath.2023.08.004_bib3","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/cncr.27773","article-title":"Survival of patients with marginal zone lymphoma: analysis of the Surveillance, Epidemiology, and End Results database","volume":"119","author":"Olszewski","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.humpath.2023.08.004_bib4","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1002\/cncr.25226","article-title":"Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy","volume":"116","author":"Goda","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.humpath.2023.08.004_bib5","doi-asserted-by":"crossref","DOI":"10.1007\/s11864-019-0687-5","article-title":"Marginal zone lymphoma: state-of-the-art treatment","volume":"20","author":"Sindel","year":"2019","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.humpath.2023.08.004_bib6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.annonc.2019.10.010","article-title":"Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Zucca","year":"2020","journal-title":"Ann Oncol : Official Journal of the European Society for Medical Oncology"},{"key":"10.1016\/j.humpath.2023.08.004_bib7","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1182\/hematology.2022000362","article-title":"Management of marginal zone lymphomas","volume":"2022","author":"Merli","year":"2022","journal-title":"Hematology American Society of Hematology Education Program"},{"key":"10.1016\/j.humpath.2023.08.004_bib8","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.3109\/10428194.2013.861067","article-title":"Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment","volume":"55","author":"Lenglet","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.humpath.2023.08.004_bib9","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1182\/blood-2002-11-3496","article-title":"Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type","volume":"102","author":"Conconi","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2023.08.004_bib10","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1016\/S2352-3026(14)00021-0","article-title":"First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial","volume":"1","author":"Salar","year":"2014","journal-title":"The Lancet Haematology"},{"key":"10.1016\/j.humpath.2023.08.004_bib11","doi-asserted-by":"crossref","first-page":"6514","DOI":"10.1182\/blood-2022-166052","article-title":"Outcome of transformed marginal zone lymphoma: a population based study","volume":"140","author":"Bult","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2023.08.004_bib12","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1093\/annonc\/mdv368","article-title":"Histologic transformation in marginal zone lymphomas\u2020","volume":"26","author":"Conconi","year":"2015","journal-title":"Ann Oncol : Official Journal of the European Society for Medical Oncology"},{"key":"10.1016\/j.humpath.2023.08.004_bib13","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2141.2008.07301.x","article-title":"High-grade transformation in splenic marginal zone lymphoma with circulating villous lymphocytes: the site of transformation influences response to therapy and prognosis","volume":"143","author":"Dungarwalla","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.humpath.2023.08.004_bib14","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1200\/JCO.18.00138","article-title":"Risk factors for transformation to higher-grade lymphoma and its impact on survival in a large cohort of patients with marginal zone lymphoma from a single institution","volume":"36","author":"Alderuccio","year":"2018","journal-title":"J Clin Oncol : Official Journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.humpath.2023.08.004_bib15","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1182\/asheducation-2015.1.625","article-title":"Treatment of patients with transformed lymphoma","volume":"2015","author":"Montoto","year":"2015","journal-title":"Hematology"},{"key":"10.1016\/j.humpath.2023.08.004_bib16","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1309\/AJCP63OGXHXCSKSC","article-title":"Marginal zone lymphomas with plasmacytic differentiation and related disorders","volume":"136","author":"Molina","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.humpath.2023.08.004_bib17","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2023.08.004_bib18","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1365-2559.2005.02309.x","article-title":"A clinicopathological study of nodal marginal zone B-cell lymphoma. A report on 21 cases","volume":"48","author":"Traverse-Glehen","year":"2006","journal-title":"Histopathology"},{"key":"10.1016\/j.humpath.2023.08.004_bib19","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1309\/AJCPZQ1GXBBNG8OG","article-title":"Immunoarchitectural patterns in nodal marginal zone B-cell lymphoma","volume":"132","author":"Salama","year":"2009","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.humpath.2023.08.004_bib20","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1097\/01.pas.0000172191.87176.3b","article-title":"Low histologic grade follicular lymphoma with high proliferation index: morphologic and clinical features","volume":"29","author":"Wang","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2023.08.004_bib21","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1182\/blood-2005-10-4079","article-title":"The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma","volume":"107","author":"Katzenberger","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2023.08.004_bib22","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1200\/JCO.18.01994","article-title":"Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III intergroup trial alliance\/CALGB 50303","volume":"37","author":"Bartlett","year":"2019","journal-title":"J Clin Oncol : Official Journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.humpath.2023.08.004_bib23","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1182\/blood.V95.6.1950","article-title":"Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients","volume":"95","author":"Berger","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2023.08.004_bib24","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1349-7006.2006.00345.x","article-title":"Clinical implications of nodal marginal zone B-cell lymphoma among Japanese: study of 65 cases","volume":"98","author":"Kojima","year":"2007","journal-title":"Cancer Sci"},{"key":"10.1016\/j.humpath.2023.08.004_bib25","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1080\/10428194.2020.1855347","article-title":"Expression of germinal center cell markers by extranodal marginal zone lymphomas of MALT type within colonized follicles, a diagnostic pitfall with follicular lymphoma","volume":"62","author":"Poveda","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.humpath.2023.08.004_bib26","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/cncr.27704","article-title":"Prognostic value of the Follicular Lymphoma International Prognostic Index score in marginal zone lymphoma: an analysis of clinical presentation and outcome in 144 patients","volume":"119","author":"Heilgeist","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.humpath.2023.08.004_bib27","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1182\/blood-2017-03-771915","article-title":"A MALT lymphoma prognostic index","volume":"130","author":"Thieblemont","year":"2017","journal-title":"Blood"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817723001697?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817723001697?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T16:42:06Z","timestamp":1758645726000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817723001697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":27,"alternative-id":["S0046817723001697"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2023.08.004","relation":{},"ISSN":["0046-8177"],"issn-type":[{"type":"print","value":"0046-8177"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The clinical significance of increased large cells in marginal zone lymphoma","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2023.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}